236 related articles for article (PubMed ID: 30109845)
1. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
[TBL] [Abstract][Full Text] [Related]
2. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Weiden PJ; Du Y; Liu CC; Stanford AD
CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
4. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Lauriello J; Claxton A; Du Y; Weiden PJ
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32841554
[TBL] [Abstract][Full Text] [Related]
5. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.
Citrome L; Yagoda S; Bidollari I; Wang M
J Clin Psychiatry; 2024 Feb; 85(1):. PubMed ID: 38416865
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
9. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
12. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Potkin SG; Risinger R; Du Y; Zummo J; Bose A; Silverman B; Stankovic S; Ehrich E
Schizophr Res; 2017 Dec; 190():115-120. PubMed ID: 28342578
[TBL] [Abstract][Full Text] [Related]
19. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
